Marc Humbert

List of Publications by Year
in descending order

849 papers	91,263 citations	399 133 h-index	443 274 g-index
933 all docs	933 docs citations	933 times ranked	47518 citing authors

#	Article	IF	Citations
1	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119.	2.2	5,074
2	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537.	2.2	3,108
3	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	2.2	2,591
4	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	2.2	2,426
5	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2015, 46, 903-975.	6.7	2,415
6	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine, 2014, 371, 1198-1207.	27.0	1,807
7	Pulmonary Arterial Hypertension in France. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1023-1030.	5.6	1,736
8	Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2004, 351, 1425-1436.	27.0	1,627
9	Cellular and molecular pathobiology of pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S13-S24.	2.8	1,322
10	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Journal of the American College of Cardiology, 2002, 40, 780-788.	2.8	1,290
11	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation, 2010, 122, 156-163.	1.6	1,264
12	Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340.	27.0	1,120
13	Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2005, 111, 3105-3111.	1.6	1,040
14	New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure. Chest, 2004, 126, 1313-1317.	0.8	923
15	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278.	2.2	903
16	The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic. Chest, 2020, 158, 106-116.	0.8	832
17	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Respiratory Journal, 2019, 54, 1901647.	6.7	806
18	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. European Respiratory Journal, 2019, 53, 1801887.	6.7	776

#	Article	IF	Citations
19	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	6.7	746
20	After asthma: redefining airways diseases. Lancet, The, 2018, 391, 350-400.	13.7	744
21	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology, 2020, 296, 172-180.	7.3	721
22	Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 165-175.	4.5	708
23	Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine, 2001, 345, 325-334.	27.0	676
24	Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis and Rheumatism, 2005, 52, 3792-3800.	6.7	656
25	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. JAMA Internal Medicine, 2021, 181, 32.	5.1	654
26	Pathologic assessment of vasculopathies in pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, S25-S32.	2.8	609
27	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	2.8	605
28	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 2002, 39, 1496-1502.	2.8	584
29	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. European Respiratory Journal, 2010, 36, 549-555.	6.7	582
30	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137.	1.6	548
31	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700889.	6.7	527
32	A global view of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 306-322.	10.7	523
33	BMPR2 Haploinsufficiency as the Inherited Molecular Mechanism for Primary Pulmonary Hypertension. American Journal of Human Genetics, 2001, 68, 92-102.	6.2	521
34	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	2.9	486
35	Severe Pulmonary Hypertension during Pregnancy. Anesthesiology, 2005, 102, 1133-1137.	2.5	483
36	Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. Journal of Clinical Investigation, 2001, 108, 1141-1150.	8.2	446

#	Article	IF	Citations
37	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. Circulation, 2015, 131, 1006-1018.	1.6	441
38	Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D51-D59.	2.8	432
39	A Novel Channelopathy in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 351-361.	27.0	412
40	Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 81-88.	5.6	405
41	Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. European Respiratory Journal, 2010, 35, 105-111.	6.7	398
42	Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. ACS Nano, 2017, 11, 112-125.	14.6	386
43	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	2.2	371
44	Mutations of the TGF-Î² type II receptorBMPR2 in pulmonary arterial hypertension. Human Mutation, 2006, 27, 121-132.	2.5	368
45	Genetics and Genomics of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D13-D21.	2.8	367
46	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nature Genetics, 2014, 46, 65-69.	21.4	351
47	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	27.8	338
48	Inflammation in Pulmonary Arterial Hypertension. Chest, 2012, 141, 210-221.	0.8	333
49	Immunosuppressive therapy in lupusâ€•and mixed connective tissue diseaseâ€“associated pulmonary arterial hypertension: A retrospective analysis of twentyâ€‘three cases. Arthritis and Rheumatism, 2008, 58, 521-531.	6.7	321
50	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2014, 43, 1691-1697.	6.7	319
51	Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. Chest, 2006, 130, 182-189.	0.8	316
52	Epidemiology and treatment of pulmonary arterial hypertension. Nature Reviews Cardiology, 2017, 14, 603-614.	13.7	310
53	Dysregulated Reninâ€“Angiotensinâ€“Aldosterone System Contributes to Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 780-789.	5.6	309
54	The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Trends in Immunology, 1999, 20, 528-533.	7.5	308

#	Article	IF	Citations
55	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	10.7	307
56	Management of Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2015, 65, 1976-1997.	2.8	296
57	Prognostic Factors for Survival in Human Immunodeficiency Virusâ€“associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1433-1439.	5.6	295
58	Pulmonary Veno-Occlusive Disease. Medicine (United States), 2008, 87, 220-233.	1.0	295
59	Right Ventricular Diastolic Impairment in Patients With Pulmonary Arterial Hypertension. Circulation, 2013, 128, 2016-2025.	1.6	294
60	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Human Pathology, 2007, 38, 893-902.	2.0	291
61	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and longâ€term survival. Arthritis and Rheumatism, 2011, 63, 3522-3530.	6.7	291
62	Pulmonary veno-occlusive disease. European Respiratory Journal, 2016, 47, 1518-1534.	6.7	289
63	Revisiting <scp>T</scp>ype 2â€high and <scp>T</scp>ype 2â€low airway inflammation in asthma: current knowledge and therapeutic implications. Clinical and Experimental Allergy, 2017, 47, 161-175.	2.9	287
64	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	6.7	287
65	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. European Respiratory Journal, 2020, 56, 2001634.	6.7	284
66	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	12.8	279
67	Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension. Circulation, 2014, 130, 2189-2208.	1.6	278
68	Deleterious Effects of Î²-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. Gastroenterology, 2006, 130, 120-126.	1.3	277
69	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. European Heart Journal, 2006, 27, 589-595.	2.2	272
70	Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1377-1383.	5.6	269
71	Pulmonary veno-occlusive disease. European Respiratory Journal, 2009, 33, 189-200.	6.7	267
72	Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) Mutation. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 851-861.	5.6	259

#	Article	IF	Citations
73	Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension. Circulation, 2006, 113, 1857-1864.	1.6	257
74	Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 311-321.	5.6	249
75	CX₃C Chemokine Fractalkine in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1419-1425.	5.6	247
76	Chemokine RANTES in Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 534-539.	5.6	239
77	Bosentan for the Treatment of Human Immunodeficiency Virusâ€"associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1212-1217.	5.6	238
78	Pulmonary Hypertension: CT of the Chest in Pulmonary Venoocclusive Disease. American Journal of Roentgenology, 2004, 183, 65-70.	2.2	234
79	Severe Pulmonary Hypertension in Histiocytosis X. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 216-223.	5.6	231
80	Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. European Respiratory Journal, 2010, 35, 1286-1293.	6.7	226
81	Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97.	2.7	226
82	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 384, 1204-1215.	27.0	224
83	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. European Respiratory Journal, 2017, 50, 1700578.	6.7	222
84	Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. European Respiratory Journal, 2012, 40, 881-885.	6.7	221
85	Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 637-643.	5.6	220
86	Overall asthma control: The relationship between current control and future risk. Journal of Allergy and Clinical Immunology, 2010, 125, 600-608.e6.	2.9	219
87	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European Heart Journal, 2010, 31, 1898-1907.	2.2	218
88	Criteria for diagnosis of exercise pulmonary hypertension. European Respiratory Journal, 2015, 46, 728-737.	6.7	213
89	2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed), 2016, 69, 177.	0.6	210
90	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218.	8.2	208

#	Article	IF	Citations
91	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757.	1.6	205
92	Survival and Prognostic Factors in Systemic Sclerosisâ€“Associated Pulmonary Hypertension: A Systematic Review and Metaâ€Analysis. Arthritis and Rheumatism, 2013, 65, 2412-2423.	6.7	205
93	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. European Respiratory Journal, 2014, 44, 1275-1288.	6.7	201
94	BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Human Mutation, 2006, 27, 212-213.	2.5	196
95	Role of Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1041-1047.	5.6	196
96	Relationship between IL-4 and IL-5 mRNA Expression and Disease Severity in Atopic Asthma. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 704-708.	5.6	191
97	Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension. Circulation Research, 2004, 94, 1263-1270.	4.5	187
98	Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. European Respiratory Journal, 2018, 51, 1702523.	6.7	186
99	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Human Mutation, 2015, 36, 1113-1127.	2.5	185
100	Prevention of Gram-Negative Translocation Reduces the Severity of Hepatopulmonary Syndrome. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 514-517.	5.6	179
101	The threeâ€year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis and Rheumatism, 2009, 60, 1831-1839.	6.7	179
102	Omalizumab in Asthma: An Update on Recent Developments. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 525-536.e1.	3.8	179
103	Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscleâ€Like Cells in Pulmonary Hypertension. Circulation, 2014, 129, 1586-1597.	1.6	178
104	Germline selection shapes human mitochondrial DNA diversity. Science, 2019, 364, .	12.6	178
105	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. Journal of Clinical Investigation, 2009, 119, 512-523.	8.2	177
106	Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. Circulation, 2009, 119, 1518-1523.	1.6	176
107	C-Kitâ€Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 116-123.	5.6	176
108	A Proof-of-Concept, Randomized, Controlled Trial of Omalizumab in Patients With Severe, Difficult-to-Control, Nonatopic Asthma. Chest, 2013, 144, 411-419.	0.8	176

#	Article	IF	Citations
109	Recommendations for Screening and Detection of Connective Tissue Diseaseâ€“Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatism, 2013, 65, 3194-3201.	6.7	175
110	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal, 2015, 45, 1303-1313.	6.7	174
111	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802095.	6.7	173
112	Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin. Journal of Allergy and Clinical Immunology, 2000, 105, 99-107.	2.9	172
113	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. European Respiratory Review, 2013, 22, 543-551.	7.1	172
114	Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 591-604.	5.7	171
115	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
116	RhoA and Rho Kinase Activation in Human Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1151-1158.	5.6	165
117	Pulmonary Edema Complicating Continuous Intravenous Prostacyclin in Pulmonary Capillary Hemangiomatosis. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1681-1685.	5.6	161
118	Local expression of Ïµ germline gene transcripts and RNA for the Ïµ heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. Journal of Allergy and Clinical Immunology, 2001, 107, 686-692.	2.9	161
119	Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era. Chest, 2011, 140, 301-309.	0.8	161
120	Pulmonary Arterial Hypertension: A Rare Complication of Primary SjÃ¶gren Syndrome. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	160
121	MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1372-1392.	5.7	160
122	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704.	1.6	155
123	Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 2014, 44, 304-323.	6.7	154
124	PATHOBIOLOGY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 451-458.	2.1	153
125	Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Human Mutation, 2011, 32, 1385-1389.	2.5	152
126	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2021, 57, 2100048.	6.7	152

#	Article	IF	Citations
127	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. Aids, 2010, 24, 67-75.	2.2	149
128	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	3.8	149
129	Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology, 2008, 48, 304-308.	1.9	148
130	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 983-997.	5.6	144
131	Severe eosinophilic asthma: a roadmap toÂconsensus. European Respiratory Journal, 2017, 49, 1700634.	6.7	143
132	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 1332-1340.	1.6	141
133	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385.	1.6	141
134	New Molecular Targets of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Chest, 2015, 147, 529-537.	0.8	140
135	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunity Reviews, 2017, 16, 1-9.	5.8	140
136	Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 873-884.	10.7	139
137	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 2018, 51, 1700745.	6.7	136
138	Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 671-678.	5.7	135
139	Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. European Respiratory Journal, 2013, 41, 1302-1307.	6.7	131
140	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis â€“ A <scp>EUFOREA</scp>â€<scp>ARIA</scp>â€<scp>EPOS</scp>â€<scp>AIRWAYS ICP</scp> statement. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1297-1305.	5.7	130
141	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Annals of the Rheumatic Diseases, 2013, 72, 1940-1946.	0.9	128
142	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
143	Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. European Respiratory Review, 2010, 19, 59-63.	7.1	127
144	Incidence and Prevalence of Chronic Thromboembolic Pulmonary Hypertension: From Acute to Chronic Pulmonary Embolism. Proceedings of the American Thoracic Society, 2006, 3, 564-567.	3.5	126

#	Article	IF	Citations
145	Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 357-362.	0.6	126
146	The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax, 2016, 71, 73-83.	5.6	126
147	Prioritised research agenda for prevention and control of chronic respiratory diseases. European Respiratory Journal, 2010, 36, 995-1001.	6.7	125
148	Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 311-322.	2.9	125
149	Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews Cardiology, 2011, 8, 526-538.	13.7	125
150	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. Journal of Clinical Investigation, 2018, 128, 1956-1970.	8.2	125
151	Evidence for the Involvement of Type I Interferon in Pulmonary Arterial Hypertension. Circulation Research, 2014, 114, 677-688.	4.5	124
152	Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. European Journal of Cardio-thoracic Surgery, 2015, 47, e105-e110.	1.4	124
153	Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736.	6.7	124
154	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134.	10.7	123
155	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
156	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	3.2	121
157	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258.	5.6	121
158	Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. European Respiratory Journal, 2010, 35, 1294-1302.	6.7	119
159	Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function inÂPulmonary Hypertension. Journal of the American College of Cardiology, 2015, 65, 668-680.	2.8	119
160	Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascular Pharmacology, 2008, 49, 113-118.	2.1	118
161	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2009, 136, 1211-1219.	0.8	117
162	RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 459-475.	2.1	116

#	Article	IF	Citations
163	Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension: Long-Term Results. Annals of Thoracic Surgery, 2012, 94, 817-824.	1.3	116
164	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 583-595.	5.6	113
165	Identification of Target Antigens of Antifibroblast Antibodies in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1128-1134.	5.6	112
166	Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 915-917.	6.7	111
167	Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
168	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. European Respiratory Journal, 2017, 50, 1700465.	6.7	111
169	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011.	5.6	111
170	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 895-904.	6.7	110
171	Early detection of pulmonary arterial hypertension. Nature Reviews Cardiology, 2015, 12, 143-155.	13.7	110
172	Systemic sclerosisâ€“related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis and Rheumatism, 2011, 63, 2456-2464.	6.7	109
173	Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colonystimulating factor and interleukin-3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopics asthmatics, and atopic and nonatopic controls. European Journal of Immunology, 1995, 25, 2727-2731.	2.9	108
174	Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis and Rheumatism, 2012, 64, 2995-3005.	6.7	108
175	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Annals of the Rheumatic Diseases, 2017, 76, 422-426.	0.9	108
176	Anti-interleukin-5 therapy in severe asthma. European Respiratory Review, 2013, 22, 251-257.	7.1	107
177	Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Research and Therapy, 2006, 8, R114.	3.5	106
178	Angiopoietin/Tie2 Pathway Influences Smooth Muscle Hyperplasia in Idiopathic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1025-1033.	5.6	106
179	Post-acute COVID-19 syndrome. European Respiratory Review, 2022, 31, 210185.	7.1	105
180	Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. Chest, 2012, 142, 1150-1157.	0.8	104

#	Article	IF	Citations
181	Safety Experience With Bosentan in 146 Children 2â€“11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance Program. Pediatric Research, 2008, 64, 200-204.	2.3	103
182	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. Circulation, 2015, 132, 834-847.	1.6	103
183	Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1061-1067.	5.6	102
184	Evaluation of Various Empirical Formulas for Estimating Mean Pulmonary Artery Pressure by Using Systolic Pulmonary Artery Pressure in Adults. Chest, 2009, 135, 760-768.	0.8	102
185	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss). European Respiratory Journal, 2016, 48, 1429-1441.	6.7	102
186	Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clinical Therapeutics, 2019, 41, 2041-2056.e5.	2.5	102
187	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	10.7	99
188	Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives. Chest, 1998, 114, 195S-199S.	0.8	97
189	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. Circulation, 2013, 128, 512-523.	1.6	97
190	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 361-371.	10.7	97
191	Pulmonary hypertension in systemic sclerosis: different phenotypes. European Respiratory Review, 2017, 26, 170056.	7.1	97
192	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy, 2009, 26, 813-825.	2.9	96
193	H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. Journal of Allergy and Clinical Immunology, 2007, 120, 827-834.	2.9	95
194	Pulmonary Artery Pressureâ€“Flow Relations after Prostacyclin in Primary Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 338-340.	5.6	94
195	Pulmonary veno-occlusive disease: Recent progress and current challenges. Respiratory Medicine, 2010, 104, S23-S32.	2.9	94
196	Early detection and management of pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 306-312.	7.1	94
197	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854.	5.6	94
198	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nature Genetics, 2013, 45, 518-521.	21.4	93

#	Article	IF	Citations
199	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. European Respiratory Journal, 2013, 41, 96-103.	6.7	92
200	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology, 2010, 49, 490-500.	1.9	91
201	Systemic Sclerosis-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1285-1293.	5.6	91
202	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. Journal of Heart and Lung Transplantation, 2012, 31, 150-158.	0.6	91
203	Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. European Respiratory Journal, 2013, 41, 578-587.	6.7	91
204	Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1493-1499.	5.6	90
205	Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm. Proceedings of the American Thoracic Society, 2006, 3, 594-600.	3.5	90
206	Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. European Respiratory Journal, 2009, 34, 1348-1356.	6.7	90
207	Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. European Respiratory Journal, 2012, 39, 1405-1414.	6.7	90
208	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. European Respiratory Journal, 2020, 56, 2001875.	6.7	90
209	Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated With Interstitial Lung Disease. Chest, 2011, 140, 1016-1024.	0.8	89
210	Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood, 2012, 119, 1772-1780.	1.4	89
211	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal, 2017, 50, 1700217.	6.7	89
212	Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax, 1999, 54, 273-277.	5.6	88
213	Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. Journal of Allergy and Clinical Immunology, 2015, 135, 1457-1464.e4.	2.9	88
214	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1273-1285.	5.6	88
215	Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations?. Chest, 2013, 143, 398-405.	0.8	87
216	Genetic counselling in a national referral centre for pulmonary hypertension. European Respiratory Journal, 2016, 47, 541-552.	6.7	87

#	Article	IF	Citations
217	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	3.2	87
218	Development and implementation of guidelines in allergic rhinitis â€“ an ARIAâ€GA²LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221.	5.7	85
219	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. European Respiratory Journal, 2011, 37, 813-822.	6.7	85
220	Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. European Respiratory Journal, 2011, 37, 1392-1399.	6.7	85
221	A Critical Role for p130^{Cas} in the Progression of Pulmonary Hypertension in Humans and Rodents. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 666-676.	5.6	85
222	The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension. Clinical Reviews in Allergy and Immunology, 2013, 44, 31-38.	6.5	85
223	Serotonin Transporter Polymorphisms in Familial and Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 798-802.	5.6	83
224	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach â€“ A MeDALL â€“ GA²LEN â€“ ARIA Position Paper. International Archives of Allergy and Immunology, 2012, 158, 216-231.	2.1	83
225	Key Role of the Endothelial TGF-Î²2/ALK1/Endoglin Signaling Pathway in Humans and Rodents Pulmonary Hypertension. PLoS ONE, 2014, 9, e100310.	2.5	83
226	Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 910-924.	1.6	83
227	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. Journal of Clinical Investigation, 2011, 121, 2888-2897.	8.2	83
228	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. European Respiratory Journal, 2022, 59, 2102419.	6.7	83
229	The CX3C chemokine fractalkine in allergic asthma and rhinitis. Journal of Allergy and Clinical Immunology, 2003, 112, 1139-1146.	2.9	82
230	High Occurrence of Hypoxemic Sleep Respiratory Disorders in Precapillary Pulmonary Hypertension and Mechanisms. Chest, 2013, 143, 47-55.	0.8	82
231	Contractile Dysfunction of Left Ventricular Cardiomyocytes in Patients With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2014, 64, 28-37.	2.8	82
232	Validation of two predictive models for survival in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 152-164.	6.7	82
233	Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respiratory Research, 2010, 11, 73.	3.6	81
234	Drug-induced pulmonary arterial hypertension: a recent outbreak. European Respiratory Review, 2013, 22, 244-250.	7.1	81

#	Article	IF	Citations
235	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. Circulation Research, 2019, 124, 846-855.	4.5	81
236	Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Annals of the Rheumatic Diseases, 2007, 66, 1610-1615.	0.9	80
237	Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22Î±â€targeted overexpression of the serotonin transporter. FASEB Journal, 2009, 23, 4135-4147.	0.5	80
238	Measuring asthma control: a comparison of three classification systems. European Respiratory Journal, 2010, 36, 269-276.	6.7	80
239	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. European Respiratory Journal, 2012, 40, 630-640.	6.7	80
240	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2014, 44, 1627-1634.	6.7	80
241	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731.	6.7	80
242	Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	5.6	80
243	Pulmonary Arterial Hypertension: Thin-Section CT Predictors of Epoprostenol Therapy Failure. Radiology, 2002, 222, 782-788.	7.3	79
244	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.8	79
245	Care pathways for the selection of a biologic in severe asthma. European Respiratory Journal, 2017, 50, 1701782.	6.7	79
246	Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology, 2020, 73, 130-139.	3.7	78
247	Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2007, 49, 1-5.	1.9	77
248	Benfluorex and Unexplained Valvular Heart Disease: A Case-Control Study. PLoS ONE, 2010, 5, e10128.	2.5	77
249	Nuclear Factor Î¤-B Is Activated in the Pulmonary Vessels of Patients with End-Stage Idiopathic Pulmonary Arterial Hypertension. PLoS ONE, 2013, 8, e75415.	2.5	77
250	Expression of the IL-4 receptor Î±-subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjectsâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 102, 859-866.	2.9	75
251	Pulmonary hypertension associated with benfluorex exposure. European Respiratory Journal, 2012, 40, 1164-1172.	6.7	75
252	Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1747-1760.	1.6	75

#	Article	IF	Citations
253	NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. Circulation, 2018, 137, 2371-2389.	1.6	75
254	Non-invasive indices of right ventricular function are markers of ventricular-arterial coupling rather than ventricular contractility: insights from a porcine model of chronic pressure overload. European Heart Journal Cardiovascular Imaging, 2013, 14, 1140-1149.	1.2	74
255	Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. Circulation, 2019, 139, 932-948.	1.6	74
256	Strategic Plan for Lung Vascular Research. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1554-1562.	5.6	73
257	Omalizumab-induced decrease of FcÉ›RI expression in patients with severe allergic asthma. Respiratory Medicine, 2010, 104, 1608-1617.	2.9	73
258	Diaphragm Muscle Fiber Weakness in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1411-1418.	5.6	72
259	T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension. Chest, 2015, 147, 1610-1620.	0.8	72
260	Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. European Respiratory Journal, 2019, 53, 1801371.	6.7	72
261	Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. European Respiratory Journal, 2020, 55, 1901592.	6.7	71
262	The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal, 2014, 44, 239-241.	6.7	70
263	An Official American Thoracic Society Statement: Pulmonary Hypertension Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 345-355.	5.6	70
264	Characterization of Kcnk3 -Mutated Rat, a Novel Model of Pulmonary Hypertension. Circulation Research, 2019, 125, 678-695.	4.5	70
265	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. Cardiovascular Research, 2020, 116, 885-893.	3.8	70
266	Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 2014, 451, 8-14.	2.1	69
267	Chemokine Macrophage Inflammatory Protein-1Î± mRNA Expression in Lung Biopsy Specimens of Primary Pulmonary Hypertension. Chest, 1998, 114, 50S-51S.	0.8	68
268	Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. European Respiratory Journal, 2009, 34, 1100-1110.	6.7	68
269	Survival in Schistosomiasis-Associated Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2010, 56, 715-720.	2.8	68
270	BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681.	6.7	68

#	Article	IF	Citations
271	Longâ€term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology, 2017, 65, 1683-1692.	7.3	68
272	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.8	68
273	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802004.	6.7	68
274	Genes and Pulmonary Arterial Hypertension. Respiration, 2007, 74, 123-132.	2.6	67
275	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respiratory Research, 2011, 12, 119.	3.6	67
276	Targeting transforming growth factor-Î² receptors in pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002341.	6.7	67
277	The 4th World Symposium on Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S1-S2.	2.8	66
278	Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension. Circulation, 2000, 102, 2460-2462.	1.6	65
279	NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respiratory Medicine, 2007, 101, 69-75.	2.9	65
280	Protein Changes Contributing to Right Ventricular Cardiomyocyte Diastolic Dysfunction in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2014, 3, e000716.	3.7	65
281	New chemokine targets for asthma therapy. Current Allergy and Asthma Reports, 2005, 5, 155-160.	5.3	64
282	Endothelin-1/Endothelin-3 Ratio. Chest, 2007, 131, 101-108.	0.8	64
283	Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. European Respiratory Review, 2017, 26, 170093.	7.1	64
284	IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1418-1429.	3.8	64
285	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. Chest, 2016, 149, 1482-1493.	0.8	63
286	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S108-S117.	2.8	62
287	Leptin signalling system as a target for pulmonary arterial hypertension therapy. European Respiratory Journal, 2015, 45, 1066-1080.	6.7	62
288	Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2018, 11, e002087.	3.6	62

#	Article	IF	Citations
289	Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2702-2714.	3.8	62
290	COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence. Journal of Allergy and Clinical Immunology, 2021, 148, 361-367.e13.	2.9	62
291	Increased Expression of High Affinity IgE (Fc É› RI) Receptor- Î± Chain mRNA and Protein-bearing Eosinophils in Human Allergen-induced Atopic Asthma. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 233-240.	5.6	61
292	Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?. International Journal of Molecular Sciences, 2018, 19, 3162.	4.1	61
293	Contrasting effects of IL-4, IL-10 and corticosteroids on RANTES production by human monocytes. International Immunology, 1996, 8, 1587-1594.	4.0	60
294	Pulmonary Hypertension Associated with Myeloproliferative Disorders: A Retrospective Study of Ten Cases. Respiration, 2008, 76, 295-302.	2.6	60
295	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. Medicine (United States), 2011, 90, 201-211.	1.0	60
296	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2011, 32, 926-926.	2.2	60
297	TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications. European Respiratory Journal, 2017, 50, 1700754.	6.7	60
298	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800678.	6.7	60
299	An Extreme Consequence of Splenectomy in Dehydrated Hereditary Stomatocytosis: Gradual Thromboâ€embolic Pulmonary Hypertension and Lungâ€“Heart Transplantation. Hemoglobin, 2003, 27, 139-147.	0.8	59
300	Screening for pulmonary arterial hypertension in systemic sclerosis. European Respiratory Review, 2019, 28, 190023.	7.1	59
301	Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respiratory Research, 2011, 12, 38.	3.6	58
302	Ca2+ handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy. Journal of Molecular and Cellular Cardiology, 2018, 118, 208-224.	1.9	58
303	Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1538-1544.	2.8	57
304	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 833-842.	0.6	57
305	Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. European Respiratory Journal, 2020, 55, 1902345.	6.7	57
306	Serum Neopterin After Lung Transplantation. Chest, 1993, 103, 449-454.	0.8	56

#	Article	IF	Citations
307	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. Arthritis and Rheumatism, 2008, 59, 867-875.	6.7	56
308	Use of Î²-Blockers in Pulmonary Hypertension. Circulation: Heart Failure, 2017, 10, .	3.9	56
309	Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine,the, 2020, 8, 461-474.	10.7	56
310	Sleep-related breathing disorders and pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002258.	6.7	56
311	INTRAPULMONARY PRODUCTION OF RANTES DURING REJECTION AND CMV PNEUMONITIS AFTER LUNG TRANSPLANTATION1. Transplantation, 1996, 61, 1757-1762.	1.0	56
312	Asthma and COVID-19: an update. European Respiratory Review, 2021, 30, 210152.	7.1	56
313	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. Chest, 2016, 149, 353-361.	0.8	55
314	Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. European Respiratory Journal, 2020, 55, 2000189.	6.7	55
315	Primary pulmonary hypertension: Current therapy. Progress in Cardiovascular Diseases, 2002, 45, 115-128.	3.1	54
316	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 189-196.	5.6	54
317	Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension: A Double-Edge Sword?. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 714-724.	2.1	54
318	Pulmonary Arterial Hypertension in the Southern Hemisphere. Chest, 2015, 147, 495-501.	0.8	54
319	Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. Circulation, 2019, 140, 1409-1425.	1.6	54
320	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. Cardiovascular Research, 2020, 116, 686-697.	3.8	54
321	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology, 2010, 49, 940-944.	1.9	53
322	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. European Respiratory Journal, 2012, 40, 75-83.	6.7	53
323	Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. European Respiratory Journal, 2015, 45, 139-149.	6.7	53
324	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. Cardiovascular Research, 2018, 114, 880-893.	3.8	52

#	Article	IF	Citations
325	Antifibroblast antibodies from systemic sclerosis patients bind to Î±-enolase and are associated with interstitial lung disease. Annals of the Rheumatic Diseases, 2010, 69, 428-433.	0.9	51
326	Cellular microparticles in the pathogenesis of pulmonary hypertension. European Respiratory Journal, 2013, 42, 272-279.	6.7	51
327	Human Immunodeficiency VirusnefSignature Sequences Are Associated with Pulmonary Hypertension. AIDS Research and Human Retroviruses, 2012, 28, 607-618.	1.1	50
328	Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension. Chest, 2012, 142, 869-876.	0.8	50
329	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. European Respiratory Journal, 2016, 47, 1028-1033.	6.7	50
330	Dasatinib increases endothelial permeability leading to pleural effusion. European Respiratory Journal, 2018, 51, 1701096.	6.7	50
331	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.6	50
332	Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. European Respiratory Journal, 2021, 58, 2004229.	6.7	50
333	Association of a KCNA5 gene polymorphism with systemic sclerosisâ€“associated pulmonary arterial hypertension in the European Caucasian population. Arthritis and Rheumatism, 2010, 62, 3093-3100.	6.7	49
334	Survivor bias and risk assessment. European Respiratory Journal, 2012, 40, 530-532.	6.7	49
335	Familial pulmonary arterial hypertension by KDR heterozygous loss of function. European Respiratory Journal, 2020, 55, 1902165.	6.7	49
336	Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discovery Today, 2014, 19, 1251-1256.	6.4	48
337	Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmunity Reviews, 2014, 13, 945-953.	5.8	48
338	Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26, 170092.	7.1	48
339	Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. Scientific Reports, 2018, 8, 1300.	3.3	48
340	Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation. Journal of Hypertension, 2018, 36, 1164-1177.	0.5	48
341	Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Advances in Therapy, 2020, 37, 718-729.	2.9	48
342	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29.	3.2	47

#	Article	IF	Citations
343	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. Journal of Nutrition, Health and Aging, 2017, 21, 92-104.	3.3	47
344	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS ONE, 2018, 13, e0197112.	2.5	47
345	Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. European Respiratory Journal, 2005, 26, 969-972.	6.7	46
346	Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis. Chest, 2010, 137, 1297-1303.	0.8	46
347	Copper Dependence of Angioproliferation in Pulmonary Arterial Hypertension in Rats and Humans. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 582-591.	2.9	46
348	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. Medicine (United States), 2015, 94, e1800.	1.0	46
349	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
350	Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal, 2022, 59, 2100396.	6.7	46
351	Update in Pulmonary Arterial Hypertension 2007. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 574-579.	5.6	45
352	Bromodomain and extraâ€tterminal protein mimic <scp>JQ1</scp> decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. Respirology, 2017, 22, 157-164.	2.3	45
353	The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 860-868.	5.6	45
354	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 586-594.	5.6	45
355	The role of combination therapy in managing pulmonary arterial hypertension. European Respiratory Review, 2014, 23, 469-475.	7.1	44
356	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. European Respiratory Journal, 2016, 48, 1517-1519.	6.7	44
357	Resting pulmonary artery pressure of 21â€“24â€…mmHg predicts abnormal exercise haemodynamics. European Respiratory Journal, 2016, 47, 1436-1444.	6.7	44
358	The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. European Respiratory Journal, 2019, 53, 1900038.	6.7	44
359	Screening strategies for pulmonary arterial hypertension. European Heart Journal Supplements, 2019, 21, K9-K20.	0.1	44
360	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 766-782.	2.4	44

#	Article	IF	Citations
361	Relation between inflammation and symptoms in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 354-367.	5.7	43
362	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. European Respiratory Journal, 2014, 44, 1069-1072.	6.7	43
363	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest, 2018, 154, 872-881.	0.8	43
364	Evaluation and management of pulmonary arterial hypertension. Respiratory Medicine, 2020, 171, 106099.	2.9	43
365	Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 531-549.	7.3	43
366	Activation of Macrophages and Cytotoxic Cells during Cytomegalovirus Pneumonia Complicating Lung Transplantations. The American Review of Respiratory Disease, 1992, 145, 1178-1184.	2.9	42
367	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Medicale, 2014, 43, e345-e363.	1.9	42
368	Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 267-279.	2.5	42
369	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. Lung, 2018, 196, 157-164.	3.3	42
370	Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. European Respiratory Journal, 2021, 57, 2004455.	6.7	42
371	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. Oncotarget, 2017, 8, 52995-53016.	1.8	42
372	Pulmonary veno-occlusive disease: advances in clinical management and treatments. Expert Review of Respiratory Medicine, 2011, 5, 217-231.	2.5	41
373	Scleroderma Lung Disease. Clinical Reviews in Allergy and Immunology, 2011, 40, 104-116.	6.5	41
374	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Annals of the Rheumatic Diseases, 2012, 71, 596-605.	0.9	41
375	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. European Respiratory Journal, 2021, 58, 2100116.	6.7	41
376	A Proof of Concept for the Detection and Classification of Pulmonary Arterial Hypertension through Breath Analysis with a Sensor Array. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 756-759.	5.6	40
377	Pulmonary arterial hypertension in idiopathic inflammatory myopathies. Medicine (United States), 2016, 95, e4911.	1.0	40
378	COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Research, 2020, 6, 00520-2020.	2.6	40

#	Article	IF	Citations
379	Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. European Respiratory Journal, 2020, 55, 1902340.	6.7	40
380	Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. European Respiratory Review, 2020, 29, 190089.	7.1	40
381	Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats. PLoS ONE, 2015, 10, e0131940.	2.5	40
382	POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respiratory Medicine, 2007, 101, 353-355.	2.9	39
383	A critical analysis of survival in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 218-222.	7.1	39
384	Risk assessment in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 390-398.	7.1	39
385	Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Annals of Allergy, Asthma and Immunology, 2020, 124, 190-196.	1.0	39
386	IN SITU PRODUCTION OF INTERLEUKIN-6 WITHIN HUMAN LUNG ALLOGRAFTS DISPLAYING REJECTION OR CYTOMEGALOVIRUS PNEUMONIA. Transplantation, 1993, 56, 623-627.	1.0	38
387	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2014, 15, 65.	3.6	38
388	Systolic and Mean Pulmonary Artery Pressures. Chest, 2015, 147, 943-950.	0.8	38
389	Right ventricular reserve in a piglet model of chronic pulmonary hypertension. European Respiratory Journal, 2015, 45, 709-717.	6.7	38
390	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Current Rheumatology Reports, 2016, 18, 10.	4.7	38
391	Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19. European Respiratory Journal, 2020, 56, 2001808.	6.7	38
392	Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. Circulation, 2021, 144, 52-73.	1.6	38
393	Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 411-420.	2.1	37
394	Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group. Journal of Rheumatology, 2010, 37, 105-115.	2.0	37
395	Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension. European Respiratory Journal, 2015, 45, 1495-1498.	6.7	37
396	Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Archives of Cardiovascular Diseases, 2017, 110, 303-316.	1.6	37

#	Article	IF	Citations
397	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2017, 36, 1234-1242.	0.6	37
398	Respiratory effects of trichloroethylene. Respiratory Medicine, 2018, 134, 47-53.	2.9	37
399	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilanceâ€“pharmacodynamic study. European Respiratory Journal, 2019, 53, 1802472.	6.7	37
400	Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. Chest, 2019, 156, 33-44.	0.8	37
401	Current Insights on the Pathogenesis of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 355-364.	2.1	36
402	Single-Cell Study of Two Rat Models of Pulmonary Arterial Hypertension Reveals Connections to Human Pathobiology and Drug Repositioning. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1006-1022.	5.6	36
403	Effect of different asthma treatments on risk of cold-related exacerbations. European Respiratory Journal, 2011, 38, 584-593.	6.7	35
404	Pre-implantation genetic diagnosis in pulmonary arterial hypertension due toBMPR2mutation: Figure 1â€“. European Respiratory Journal, 2012, 39, 1534-1535.	6.7	35
405	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2015, 46, 1851-1853.	6.7	35
406	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. Drug Safety, 2016, 39, 287-294.	3.2	35
407	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1102-1111.	5.6	35
408	Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Annals of the Rheumatic Diseases, 2010, 69, 1360-1363.	0.9	34
409	Estimating Right Ventricular Stroke Work and the Pulsatile Work Fraction in Pulmonary Hypertension. Chest, 2013, 143, 1343-1350.	0.8	34
410	Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 457-467.	0.6	34
411	Resident PW1 ⁺ Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. Circulation Research, 2016, 118, 822-833.	4.5	34
412	Gutâ€“Lung Connection in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 402-405.	2.9	34
413	Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. Expert Opinion on Therapeutic Targets, 2017, 21, 181-190.	3.4	34
414	Review: Therapeutic advances in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2008, 2, 249-265.	2.6	33

#	Article	IF	Citations
415	Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2. Chest, 2015, 147, 1385-1394.	0.8	33
416	Multimodal Imaging Mass Spectrometry to Identify Markers of Pulmonary Arterial Hypertension in Human Lung Tissue Using MALDI-ToF, ToF-SIMS, and Hybrid SIMS. Analytical Chemistry, 2020, 92, 12079-12087.	6.5	33
417	Hyperplasia of Pulmonary Artery Smooth Muscle Cells Is Causally Related to Overexpression of the Serotonin Transporter in Primary Pulmonary Hypertension. Chest, 2002, 121, 97S-98S.	0.8	32
418	Pulmonary arterial hypertension masquerading as severe refractory asthma. European Respiratory Journal, 2008, 32, 513-516.	6.7	32
419	Update in Pulmonary Hypertension 2008. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 650-656.	5.6	32
420	Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension. European Respiratory Journal, 2017, 49, 1601897.	6.7	32
421	Pulmonary Hypertension in Parenchymal Lung Diseases. Chest, 2018, 153, 217-223.	0.8	32
422	Severe T2-high asthma in the biologics era: European experts' opinion. European Respiratory Review, 2019, 28, 190054.	7.1	32
423	Lung transplantation for sarcoidosis: outcome and prognostic factors. European Respiratory Journal, 2021, 58, 2003358.	6.7	32
424	Prostacyclin for pulmonary arterial hypertension. The Cochrane Library, 2019, 2019, CD012785.	2.8	32
425	Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. European Respiratory Review, 2009, 18, 272-290.	7.1	31
426	Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. European Respiratory Journal, 2010, 35, 6-8.	6.7	31
427	Small platelet microparticle levels are increased in pulmonary arterial hypertension. European Journal of Clinical Investigation, 2013, 43, 64-71.	3.4	31
428	Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. European Respiratory Journal, 2016, 48, 254-257.	6.7	31
429	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	6.7	31
430	Sex and gender in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 200330.	7.1	31
431	Severe pulmonary arterial hypertension in type 1 glycogen storage disease. European Journal of Pediatrics, 2002, 161, S93-S96.	2.7	30
432	Pulmonary hypertension complicating sarcoidosis. Presse Medicale, 2012, 41, e303-e316.	1.9	30

#	Article	IF	Citations
433	Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway. Thrombosis and Haemostasis, 2014, 112, 1002-1013.	3.4	30
434	Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 342-355.	5.6	30
435	Rare respiratory diseases are ready for primetime: from Rare Disease Day to the European Reference Networks. European Respiratory Journal, 2017, 49, 1700085.	6.7	30
436	An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. Nature Communications, 2021, 12, 1720.	12.8	30
437	Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. Aids, 2005, 19, 1239-1240.	2.2	29
438	Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. European Respiratory Journal, 2010, 36, 202-204.	6.7	29
439	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. Annals of Thoracic Surgery, 2017, 104, 404-411.	1.3	29
440	Factors predicting outcome after pulmonary endarterectomy. PLoS ONE, 2018, 13, e0198198.	2.5	29
441	Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	3.6	29
442	L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Presse Medicale, 2013, 42, 507-510.	1.9	28
443	Drugs induced pulmonary arterial hypertension. Presse Medicale, 2013, 42, e303-e310.	1.9	28
444	Update in systemic sclerosis-associated pulmonary arterial hypertension. Presse Medicale, 2014, 43, e293-e304.	1.9	28
445	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry. International Journal of Cardiology, 2014, 172, 561-567.	1.7	28
446	Interferon-induced pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2016, 22, 415-420.	2.6	28
447	Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respiratory Medicine, 2019, 154, 69-75.	2.9	28
448	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. European Respiratory Journal, 2020, 56, 2000279.	6.7	28
449	How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1081-1088.	3.8	28
450	Serum and pulmonary uric acid in pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000332.	6.7	28

#	Article	IF	Citations
451	Inhibition of B cellâ€“dependent lymphoid follicle formation prevents lymphocytic bronchiolitis after lung transplantation. JCI Insight, 2019, 4, .	5.0	28
452	Systematic Analysis of Blood Cell Transcriptome in End-Stage Chronic Respiratory Diseases. PLoS ONE, 2014, 9, e109291.	2.5	28
453	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. European Respiratory Review, 2022, 31, 210165.	7.1	28
454	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 716-721.	0.6	28
455	Strong linear relationship between heart rate and mean pulmonary artery pressure in exercising patients with severe precapillary pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H769-H777.	3.2	27
456	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2015, 15, 13-26.	2.2	27
457	Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension. Biomolecules, 2020, 10, 1261.	4.0	27
458	Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. European Respiratory Journal, 2022, 60, 2103181.	6.7	27
459	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760.	5.6	27
460	Human Î³-Herpesviruses Epstein-Barr Virus and Human Herpesvirus-8 Are Not Detected in the Lungs of Patients With Severe Pulmonary Arterial Hypertension. Chest, 2011, 139, 1310-1316.	0.8	26
461	ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension. Clinical Genetics, 2012, 82, 173-179.	2.0	26
462	Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. Chest, 2013, 144, 1512-1520.	0.8	26
463	Chronic thromboembolic pulmonary hypertension. Presse Medicale, 2015, 44, e409-e416.	1.9	26
464	Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800279.	6.7	26
465	Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENTâ€1/â€2 studies. Pulmonary Circulation, 2018, 8, 1-4.	1.7	26
466	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901486.	6.7	26
467	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 295-304.	5.6	26
468	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. Cardiovascular Research, 2022, 118, 1805-1820.	3.8	26

#	Article	IF	Citations
469	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Chest, 2022, 161, 219-231.	0.8	26
470	Mediators involved in HIV-related pulmonary arterial hypertension. Aids, 2008, 22, S41-S47.	2.2	25
471	Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. European Respiratory Journal, 2010, 36, 1209-1211.	6.7	25
472	Pulmonary veno-occlusive disease: The bÃªte noire of pulmonary hypertension in connective tissue diseases?. Presse Medicale, 2011, 40, e87-e100.	1.9	25
473	Impression, Sunset. Circulation, 2013, 127, 1098-1100.	1.6	25
474	Asthma: still a promising future?. European Respiratory Review, 2014, 23, 405-407.	7.1	25
475	Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. Proteomics, 2016, 16, 2637-2649.	2.2	25
476	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. Journal of Cardiac Failure, 2017, 23, 29-35.	1.7	25
477	Pulmonary hypertension associated with neurofibromatosis type 1. European Respiratory Review, 2018, 27, 180053.	7.1	25
478	Allergen-induced recruitment of FcÏƒRI+ eosinophils in human atopic skin. European Journal of Immunology, 1997, 27, 1236-1241.	2.9	24
479	Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Current Opinion in Pulmonary Medicine, 2010, 16, S1-S9.	2.6	24
480	Progress in Pulmonary Arterial Hypertension Pathology: Relighting a Torch Inside the Tunnel. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 210-212.	5.6	24
481	Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells. Respiratory Research, 2015, 16, 114.	3.6	24
482	Heritable pulmonary hypertension: from bench to bedside. European Respiratory Review, 2017, 26, 170037.	7.1	24
483	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. European Respiratory Journal, 2020, 55, 1802108.	6.7	24
484	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 118-131.	2.9	24
485	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. Journal of Heart and Lung Transplantation, 2021, 40, 1009-1018.	0.6	24
486	Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2003, 20, 9-19.	0.2	24

#	Article	IF	Citations
487	Ciclesonide: a novel inhaled corticosteroid. Expert Opinion on Investigational Drugs, 2004, 13, 1349-1360.	4.1	23
488	Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S.	0.8	23
489	Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. European Respiratory Review, 2009, 18, 42-46.	7.1	23
490	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2011, 12, 1585-1596.	1.8	23
491	Chronic thromboembolic pulmonary hypertension: advances from bench to patient management. European Respiratory Journal, 2013, 41, 8-9.	6.7	23
492	Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 1195-1198.	6.7	23
493	CardioPulse ArticlesWhat's new in the European Society of Cardiology/European Respiratory Society Pulmonary Hypertension Guidelines?The Ten Commandments for 2015 European Society of Cardiologyâ€“European Respiratory Society Guidelines on Pulmonary HypertensionNewEHJinternational editorial board membersEHJSupplementâ€”the Heart of the Matter, UPDATE: Table 1. European Heart Journal, 2016, 37, 4-11.	2.2	23
494	No genetic association detected with mepolizumab efficacy in severe asthma. Respiratory Medicine, 2017, 132, 178-180.	2.9	23
495	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovascular Research, 2021, 117, 1391-1401.	3.8	23
496	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	2.9	23
497	Sildenafil for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 6-7.	5.6	22
498	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1193-1205.	3.3	22
499	Comparison of hemodynamic parameters in treatment-naÃ¯ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519.	0.6	22
500	Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2018, 154, 521-531.	0.8	22
501	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB Journal, 2019, 33, 3670-3679.	0.5	22
502	Pulmonary arterial hypertension in ANCA-associated vasculitis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2006, 23, 223-8.	0.2	22
503	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2022, 60, 2200803.	6.7	22
504	The association between resting and mild-to-moderate exercise pulmonary artery pressure. European Respiratory Journal, 2012, 39, 313-318.	6.7	21

#	Article	IF	Citations
505	Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1). Chest, 2012, 142, 1027A.	0.8	21
506	T-type Ca2+ channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 1631-1641.	4.1	21
507	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. European Respiratory Review, 2018, 27, 180004.	7.1	21
508	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 4105.	4.1	21
509	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. European Respiratory Journal, 2018, 52, 1800272.	6.7	21
510	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 2021, 12, 7104.	12.8	21
511	Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction. Respiration, 2013, 85, 471-477.	2.6	20
512	KCNK3: new gene target for pulmonary hypertension?. Expert Review of Respiratory Medicine, 2014, 8, 385-387.	2.5	20
513	Right ventricular plasticity in a porcine model of chronic pressure overload. Journal of Heart and Lung Transplantation, 2014, 33, 194-202.	0.6	20
514	New pharmacotherapy options for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2015, 16, 2113-2131.	1.8	20
515	Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. Journal of Medicinal Chemistry, 2018, 61, 2725-2736.	6.4	20
516	Rapid Contour-based Segmentation for ¹⁸F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation. Radiology, 2018, 288, 277-284.	7.3	20
517	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. Journal of Heart and Lung Transplantation, 2018, 37, 1102-1110.	0.6	20
518	In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression. Respiratory Research, 2020, 21, 186.	3.6	20
519	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. Cardiovascular Research, 2021, 117, 2474-2488.	3.8	20
520	Use of Amplatzer Fenestrated Atrial Septal Defect Device in a Child with Familial Pulmonary Hypertension. Pediatric Cardiology, 2006, 27, 759-762.	1.3	19
521	Current management approaches to portopulmonary hypertension. International Journal of Clinical Practice, 2011, 65, 11-18.	1.7	19
522	Severe Pulmonary Hypertension Associated With Emphysema. Chest, 2012, 142, 1654-1658.	0.8	19

#	Article	IF	Citations
523	Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath. Annales Pharmaceutiques Francaises, 2013, 71, 203-215.	1.0	19
524	An Update on Medical Therapy for Pulmonary Arterial Hypertension. Current Hypertension Reports, 2013, 15, 614-622.	3.5	19
525	Should we use gait speed in COPD, FEV‹sub›1‹/sub›in frailty and dyspnoea in both?. European Respiratory Journal, 2016, 48, 315-319.	6.7	19
526	Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?. Current Hypertension Reports, 2017, 19, 86.	3.5	19
527	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. American Journal of Pathology, 2019, 189, 1159-1175.	3.8	19
528	Excitation-contraction coupling and relaxation alteration in right ventricular remodelling caused by pulmonary arterial hypertension. Archives of Cardiovascular Diseases, 2020, 113, 70-84.	1.6	19
529	A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. Chest, 2021, 159, 791-797.	0.8	19
530	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	5.6	19
531	Severe pulmonary arterial hypertension in type 1 glycogen storage disease. European Journal of Pediatrics, 2002, 161, S93-S96.	2.7	18
532	TGFÎ² receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. Annals of the Rheumatic Diseases, 2012, 71, 1900-1903.	0.9	18
533	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension. Chest, 2018, 154, 136-147.	0.8	18
534	The Thousand Faces of Leptin in the Lung. Chest, 2021, 159, 239-248.	0.8	18
535	Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls. European Respiratory Journal, 2021, 58, 2101090.	6.7	18
536	Serotonin Transporter and Receptors in Various Forms of Human Pulmonary Hypertension. Chest, 2005, 128, 552S-553S.	0.8	17
537	Enhanced glucocorticoidâ€induced leucine zipper in dendritic cells induces allergenâ€specific regulatory ‹scp›CD‹/scp›4‹sup›+‹/sup›‹scp›T‹/scp›â€cells in respiratory allergies. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 624-631.	5.7	17
538	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2209-2221.	5.6	17
539	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration, 2018, 95, 244-250.	2.6	17
540	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 166-174.	5.6	17

#	Article	IF	Citations
541	Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous. International Journal of Molecular Sciences, 2019, 20, 3575.	4.1	17
542	The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats. International Journal of Molecular Sciences, 2019, 20, 1527.	4.1	17
543	An update on sarcoidosis-associated pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2020, 26, 582-590.	2.6	17
544	Pulmonary capillary haemangiomatosis: a distinct entity?. European Respiratory Review, 2020, 29, 190168.	7.1	17
545	Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm. European Journal of Pediatrics, 2021, 180, 2379-2387.	2.7	17
546	Endothelin Receptor Antagonists. Handbook of Experimental Pharmacology, 2013, 218, 199-227.	1.8	17
547	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Annals of Cardiothoracic Surgery, 2022, 11, 106-119.	1.7	17
548	Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nature Clinical Practice Rheumatology, 2005, 1, 93-101.	3.2	16
549	Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 551-552.	5.6	16
550	Inflammatory Mechanisms in HIV-Associated Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 645-653.	2.1	16
551	GINA 2015: the latest iteration of a magnificent journey. European Respiratory Journal, 2015, 46, 579-582.	6.7	16
552	A prospective study of the 6â€…min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naÃ¯ve systemic sclerosis-associated pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2016, 75, 1457-1465.	0.9	16
553	Genetics of pulmonary hypertension in the clinic. Current Opinion in Pulmonary Medicine, 2017, 23, 386-391.	2.6	16
554	Validation of a risk assessment instrument for pulmonary arterial hypertension. European Heart Journal, 2018, 39, 4182-4185.	2.2	16
555	Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?. Blood Reviews, 2019, 37, 100579.	5.7	16
556	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000653.	6.7	16
557	Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. ERJ Open Research, 2022, 8, 00479-2021.	2.6	16
558	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 573-583.	5.6	16

#	Article	IF	Citations
559	Montelukast in guidelines and beyond. Advances in Therapy, 2009, 26, 575-587.	2.9	15
560	Pharmacokinetic evaluation of continuous intravenous epoprostenol. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1587-1598.	3.3	15
561	The study of risk in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 234-238.	7.1	15
562	Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure. Respiration, 2013, 85, 464-470.	2.6	15
563	A Critical Appraisal of the Updated 2014 Nice Pulmonary Hypertension Classification System. Canadian Journal of Cardiology, 2015, 31, 367-374.	1.7	15
564	Novel targets of omalizumab in asthma. Current Opinion in Pulmonary Medicine, 2017, 23, 56-61.	2.6	15
565	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. Journal of Heart and Lung Transplantation, 2017, 36, 386-398.	0.6	15
566	A genome-wide association analysis identifies PDE1A|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population. Oncotarget, 2017, 8, 74917-74926.	1.8	15
567	Right heart catheterisation is still a fundamental part of the follow-up assessment of pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800738.	6.7	15
568	Lysyl oxidaseâ€"a possible role in systemic sclerosisâ€"associated pulmonary hypertension: a multicentre study. Rheumatology, 2019, 58, 1547-1555.	1.9	15
569	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. European Respiratory Journal, 2019, 54, 1900585.	6.7	15
570	A novel secreted-cAMP pathway inhibits pulmonary hypertension via a feed-forward mechanism. Cardiovascular Research, 2020, 116, 1500-1513.	3.8	15
571	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS ONE, 2020, 15, e0243961.	2.5	15
572	2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. Russian Journal of Cardiology, 2016, , 5-64.	1.4	15
573	Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. European Respiratory Journal, 2022, 60, 2103130.	6.7	15
574	An emerging phenotype of pulmonary arterial hypertension patients carryingSOX17variants. European Respiratory Journal, 2022, 60, 2200656.	6.7	15
575	Mutations de gÃ¨nes codant pour des rÃ©cepteurs du TGF-Î² (BMPR-2 et ALK-1) dans les hypertensions artÃ©rielles pulmonaires primitives. SociÃ©tÃ© De Biologie Journal, 2002, 196, 53-58.	0.3	14
576	Asthma management: Are GINA guidelines appropriate for daily clinical practice?. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2005, 14, 294-302.	2.3	14

#	Article	IF	Citations
577	A decade of achievement in pulmonary hypertension. European Respiratory Review, 2011, 20, 215-217.	7.1	14
578	Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries. Thrombosis and Haemostasis, 2012, 108, 1049-1060.	3.4	14
579	Pulmonary complications of type 1 neurofibromatosis. Revue Des Maladies Respiratoires, 2016, 33, 460-473.	1.7	14
580	Managing asthma in the era of biological therapies. Lancet Respiratory Medicine,the, 2017, 5, 376-378.	10.7	14
581	Proteomic Analysis of KCNK3 Loss of Expression Identified Dysregulated Pathways in Pulmonary Vascular Cells. International Journal of Molecular Sciences, 2020, 21, 7400.	4.1	14
582	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest, 2021, 159, 1197-1207.	0.8	14
583	Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. European Respiratory Journal, 2021, 58, 2004066.	6.7	14
584	Pulmonary hypertension related to drugs and toxins. Current Opinion in Cardiology, 1999, 14, 437.	1.8	14
585	The Right Tools at the Right Time. Chest, 2006, 130, 29S-40S.	0.8	13
586	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1â€“. European Respiratory Journal, 2012, 39, 1549-1550.	6.7	13
587	New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension. European Respiratory Review, 2013, 22, 495-502.	7.1	13
588	CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 Polymorphisms in Patients With Bosentan-Induced Liver Toxicity. Clinical Pharmacology and Therapeutics, 2014, 95, 583-585.	4.7	13
589	A roadmap for management of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 54, 1901295.	6.7	13
590	Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension. Chest, 2019, 155, 991-998.	0.8	13
591	Survival Improved in Patients AgedÂâ‰ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest, 2020, 157, 945-954.	0.8	13
592	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	2.9	13
593	Recent advances in the management of pulmonary hypertension with interstitial lung disease. European Respiratory Review, 2022, 31, 210220.	7.1	13
594	Biologics in asthma: difficulties and drawbacks. Expert Opinion on Biological Therapy, 2008, 8, 1921-1928.	3.1	12

#	Article	IF	Citations
595	Vasodilators in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 202-203.	5.6	12
596	Pulmonary arterial hypertension: bridging the present to the future. European Respiratory Review, 2012, 21, 267-270.	7.1	12
597	Global effort against rare and orphan diseases. European Respiratory Review, 2012, 21, 171-172.	7.1	12
598	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. Chest, 2016, 150, 256-258.	0.8	12
599	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 537-541.	5.6	12
600	Seeing the Forest for the (Arterial) Tree: Vascular Pruning and the Chronic Obstructive Pulmonary Disease Pulmonary Vascular Phenotype. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 406-408.	5.6	12
601	Functional interaction between PDGFÎ² and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L445-L455.	2.9	12
602	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 843-852.	5.6	12
603	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. European Respiratory Journal, 2021, 57, 2002208.	6.7	12
604	Integrating haemodynamics identifies an extreme pulmonary hypertension phenotype. European Respiratory Journal, 2021, 58, 2004625.	6.7	12
605	Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort. Journal of Heart and Lung Transplantation, 2022, 41, 445-457.	0.6	12
606	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respiratory Medicine, 2010, 104, S74-S80.	2.9	11
607	ERS publications: the flagship and the fleet. European Respiratory Journal, 2012, 40, 535-537.	6.7	11
608	Plasma Levels of High-Density Lipoprotein Cholesterol Are Not Associated with Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 107-107.	5.6	11
609	Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries. Progress in Respiratory Research, 2012, , 85-93.	0.1	11
610	Idiopathic Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 560-567.	2.1	11
611	Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. European Respiratory Journal, 2014, 43, 641-643.	6.7	11
612	The ambition of the European Respiratory Journal: chapter 3. European Respiratory Journal, 2015, 45, 1-6.	6.7	11

#	Article	IF	Citations
613	Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting Î²2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Respiratory Medicine, 2018, 141, 111-120.	2.9	11
614	Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 942-946.	5.7	11
615	The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. Lancet Rheumatology, The, 2021, 3, e149-e159.	3.9	11
616	PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. Orphanet Journal of Rare Diseases, 2021, 16, 196.	2.7	11
617	Endothelin Receptor Antagonists. Handbook of Experimental Pharmacology, 2013, , 199-227.	1.8	11
618	Temporal Asthma Patterns Using Repeated Questionnaires over 13 Years in a Large French Cohort of Women. PLoS ONE, 2013, 8, e65090.	2.5	11
619	The Beneficial Effect of Suramin on Monocrotaline-Induced Pulmonary Hypertension in Rats. PLoS ONE, 2013, 8, e77073.	2.5	11
620	Role of Store-Operated Ca2+ Entry in the Pulmonary Vascular Remodeling Occurring in Pulmonary Arterial Hypertension. Biomolecules, 2021, 11, 1781.	4.0	11
621	Understanding the Role of CD4+CD25^{high} (So-Called Regulatory) T Cells in Idiopathic Pulmonary Arterial Hypertension. Respiration, 2008, 75, 253-256.	2.6	10
622	Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis. European Respiratory Review, 2010, 19, 349-351.	7.1	10
623	Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension. PLoS ONE, 2015, 10, e0134221.	2.5	10
624	Usefulness of Cardiovascular Magnetic Resonance IndicesÂto Rule In or Rule Out Precapillary Pulmonary Hypertension. Canadian Journal of Cardiology, 2015, 31, 1469-1476.	1.7	10
625	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 338-347.	0.6	10
626	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 647-656.	0.6	10
627	Homoarginine predicts mortality in treatment-naive patients with pulmonary arterial hypertension. International Journal of Cardiology, 2016, 217, 12-15.	1.7	10
628	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. Chest, 2018, 154, 882-892.	0.8	10
629	Ultra-rare disease: an European perspective. European Respiratory Review, 2020, 29, 200195.	7.1	10
630	Right Ventricle Remodeling Metabolic Signature in Experimental Pulmonary Hypertension Models of Chronic Hypoxia and Monocrotaline Exposure. Cells, 2021, 10, 1559.	4.1	10

#	Article	IF	Citations
631	Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2021, 22, 9105.	4.1	10
632	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. Archivos De Bronconeumologia, 2020, 56, 578-585.	0.8	10
633	SUR1 as a New Therapeutic Target for Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	2.9	10
634	Pulmonary Venoocclusive Disease and Failure of Specific Therapy. Chest, 2009, 136, 1181.	0.8	9
635	Predicting Survival in Pulmonary Arterial Hypertension. Chest, 2011, 139, 1263-1264.	0.8	9
636	Novel Medical Therapies for Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2013, 34, 867-880.	2.1	9
637	The ambition of the European Respiratory Journal. European Respiratory Journal, 2013, 41, 1-2.	6.7	9
638	Telomere Maintenance Is a Critical Determinant in the Physiopathology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2015, 66, 1942-1943.	2.8	9
639	Medical Treatment of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 686-700.	2.1	9
640	Controversies and opportunities in severe asthma. Current Opinion in Pulmonary Medicine, 2018, 24, 83-93.	2.6	9
641	Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosusâ€associated pulmonary arterial hypertension. ESC Heart Failure, 2019, 6, 1322-1325.	3.1	9
642	Hospital burden of pulmonary arterial hypertension in France. PLoS ONE, 2019, 14, e0221211.	2.5	9
643	An insider view on the World Symposium on Pulmonary Hypertension. Lancet Respiratory Medicine,the, 2019, 7, 484-485.	10.7	9
644	Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SVâ€INHIBITION study design. ESC Heart Failure, 2020, 7, 747-756.	3.1	9
645	Pulmonary Endothelin-1 Clearance in Human Pulmonary Arterial Hypertension. Chest, 2005, 128, 622S.	0.8	8
646	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research and Therapy, 2011, 13, 114.	3.5	8
647	Whistleblowers. European Respiratory Journal, 2011, 38, 510-511.	6.7	8
648	Pulmonary Arterial Hypertension in a Patient With Cowden Syndrome and Anorexigen Exposure. Chest, 2011, 140, 1066-1068.	0.8	8

#	Article	IF	Citations
649	Circulating fibrocytes and pulmonary arterial hypertension. European Respiratory Journal, 2012, 39, 210-212.	6.7	8
650	Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. European Respiratory Journal, 2015, 46, 283-286.	6.7	8
651	Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues. European Respiratory Journal, 2017, 50, 1701319.	6.7	8
652	Pulmonary arterial hypertension registries: past, present and into the future. European Respiratory Review, 2019, 28, 190128.	7.1	8
653	Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. Journal of Asthma, 2021, 58, 849-854.	1.7	8
654	The â€˜great waitâ€™ for diagnosis in pulmonary arterial hypertension. Respirology, 2020, 25, 790-792.	2.3	8
655	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission and role for pre-test probability scores and home treatment. European Respiratory Journal, 2021, 58, 2101033.	6.7	8
656	Right ventricle dysfunction in patients with acute pulmonary embolism supposedly at low risk for death: when evidence-based medicine rescues clinical practice. European Heart Journal, 2021, 42, 3200-3202.	2.2	8
657	Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315.	3.2	8
658	Neonatal diagnosis of HIV infection. Lancet, The, 1991, 338, 631.	13.7	7
659	Endothelin A receptor blockade improves regression of flow-induced pulmonary vasculopathy in piglets. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, 677-683.	0.8	7
660	Letter by Montani et al Regarding Article, â€œElevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertensionâ€• Circulation, 2011, 123, e614; author reply e615.	1.6	7
661	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2014, 8, 84-92.	2.6	7
662	Rare (pulmonary) disease day: â€œfeeding the breath, energy for life!â€• European Respiratory Journal, 2015, 45, 297-300.	6.7	7
663	A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. European Respiratory Review, 2016, 25, 93-96.	7.1	7
664	Challenging the concept of adding more drugs in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1701527.	6.7	7
665	Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1532-1542.e5.	0.8	7
666	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. European Respiratory Journal, 2021, 58, 2100466.	6.7	7

#	Article	IF	Citations
667	Success and continuous growth of the ERS clinical research collaborations. European Respiratory Journal, 2021, 58, 2102527.	6.7	7
668	Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clinical and Experimental Rheumatology, 2010, 28, S47-52.	0.8	7
669	Lung transplantation in HIV-positive patients: a European retrospective cohort study. European Respiratory Journal, 2022, 60, 2200189.	6.7	7
670	Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. British Journal of Clinical Pharmacology, 2022, 88, 5227-5237.	2.4	7
671	PERFORIN AND GRANZYME B GENE-EXPRESSING CELLS IN BRONCHOALVEOLAR LAVAGE FLUIDS FROM LUNG ALLOGRAFT RECIPIENTS DISPLAYING CYTOMEGALOVIRUS PNEUMONITIS. Transplantation, 1994, 57, 1289-1292.	1.0	6
672	Immunologic Therapeutic Interventions in Asthma. Clinics in Chest Medicine, 2012, 33, 585-597.	2.1	6
673	The ambition of the European Respiratory Journal: chapter 2. European Respiratory Journal, 2014, 43, 1-2.	6.7	6
674	Perceived 10-year change in respiratory health: Reliability and predictive ability. Respiratory Medicine, 2015, 109, 188-199.	2.9	6
675	Blood Eosinophils and Serum IgE Predict Response to Omalizumab in Patients with Severe Allergic Asthma: Innovate Trial Post-Hoc Analysis. Journal of Allergy and Clinical Immunology, 2016, 137, AB16.	2.9	6
676	Clinical trials: registration and transparency. European Respiratory Journal, 2016, 47, 1342-1344.	6.7	6
677	Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 704-706.	5.6	6
678	POINT: Should Initial Combination Therapy Be the Standard of Care in Pulmonary Arterial Hypertension? Yes. Chest, 2019, 156, 1039-1042.	0.8	6
679	Pulmonary arterial hypertension in systemic sclerosis. Presse Medicale, 2021, 50, 104062.	1.9	6
680	European Respiratory Society clinical practice guidelines: methodological guidance. ERJ Open Research, 2022, 8, 00655-2021.	2.6	6
681	Finding Pulmonary Arterial Hypertensionâ€"Switching to Offense to Mitigate Disease Burden. JAMA Cardiology, 2022, 7, 369.	6.1	6
682	Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. Annals of Cardiothoracic Surgery, 2022, 11, 143-150.	1.7	6
683	Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery. European Respiratory Review, 2021, 30, 210166.	7.1	6
684	Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 1285-1293.	0.6	6

#	Article	IF	Citations
685	The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries. European Respiratory Review, 2012, 21, 4-5.	7.1	5
686	Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease. Circulation, 2012, 125, 2045-2047.	1.6	5
687	You say goodbye, and I say hello!. European Respiratory Review, 2012, 21, 265-266.	7.1	5
688	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2015, 46, 1211-1214.	6.7	5
689	Toward better management of rare and orphan pulmonary diseases. European Respiratory Journal, 2016, 47, 1334-1335.	6.7	5
690	Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease. Presse Medicale, 2017, 46, 1223-1225.	1.9	5
691	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. International Journal of Clinical Pharmacy, 2018, 40, 790-794.	2.1	5
692	Guidance production before evidence generation for critical issues: the example of COVID-19. European Respiratory Review, 2020, 29, 200310.	7.1	5
693	Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. Chest, 2020, 158, 2602-2609.	0.8	5
694	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. British Journal of Anaesthesia, 2020, 125, e466-e468.	3.4	5
695	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. Archivos De Bronconeumologia, 2020, 56, 578-585.	0.8	5
696	Lung transplantation in neonates and infants: ESPNIC survey of European neonatologists and pediatric intensivists. European Journal of Pediatrics, 2021, 180, 295-298.	2.7	5
697	The isobaric pulmonary arterial compliance in pulmonary hypertension. ERJ Open Research, 2021, 7, 00941-2020.	2.6	5
698	Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study. Pulmonary Circulation, 2021, 11, 1-9.	1.7	5
699	Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiographyâ€based cluster analysis. American Journal of Hematology, 2021, 96, 1166-1175.	4.1	5
700	Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study. Journal of Asthma and Allergy, 2021, Volume 14, 1129-1138.	3.4	5
701	Investigating the association between ALK Receptor Tyrosine Kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database. European Respiratory Journal, 2021, 58, 2101576.	6.7	5
702	PlateletâEDerived Growth Factor Receptor Type Î± Activation Drives Pulmonary Vascular Remodeling Via Progenitor Cell Proliferation and Induces Pulmonary Hypertension. Journal of the American Heart Association, 2022, 11, e023021.	3.7	5

#	Article	IF	Citations
703	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 210161.	7.1	5
704	Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units. European Respiratory Journal, 2022, 60, 2200107.	6.7	5
705	New Formula for Predicting Mean Pulmonary Artery Pressure. Chest, 2005, 128, 467.	0.8	4
706	Update on the European Respiratory Review. European Respiratory Journal, 2010, 36, 993-994.	6.7	4
707	Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). Journal of Rheumatology, 2011, 38, 2419-2427.	2.0	4
708	Future perspectives on rare pulmonary diseases and rare presentations of common disorders. European Respiratory Review, 2013, 22, 199-201.	7.1	4
709	Response to Letter Regarding Article, â€œMitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Modelâ€. Circulation, 2016, 133, e592-3.	1.6	4
710	Targeting immunoglobulin E in non-atopic asthma: crossing the red line?. European Respiratory Journal, 2016, 48, 1538-1540.	6.7	4
711	The ambition of the European Respiratory Journal: chapter 4. European Respiratory Journal, 2016, 47, 1-4.	6.7	4
712	Pulmonary veno-occlusive disease as an occupational lung disease. Lancet Respiratory Medicine,the, 2017, 5, e19.	10.7	4
713	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. Rheumatology, 2017, 56, v33-v37.	1.9	4
714	Are indexed values better for defining exercise pulmonary hypertension?. European Respiratory Journal, 2017, 50, 1700240.	6.7	4
715	Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus. ERJ Open Research, 2018, 4, 00081-2018.	2.6	4
716	Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). Pulmonary Circulation, 2020, 10, 1-10.	1.7	4
717	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary venoâ€occlusive disease. Pulmonary Circulation, 2020, 10, 1-4.	1.7	4
718	Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 675-677.	5.6	4
719	Pulmonary Endarterectomy in Patients With Myeloproliferative Neoplasms. Chest, 2022, 161, 552-556.	0.8	4
720	Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. International Journal of Clinical Pharmacy, 2020, 42, 1128-1138.	2.1	4

#	Article	IF	Citations
721	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. Frontiers in Medicine, 2022, 9, 851935.	2.6	4
722	Sildenafil for Pulmonary Hypertension in Pregnancy?. Anesthesiology, 2006, 104, 383-383.	2.5	3
723	Prise enÂcharge diagnostique etÂthÃ©rapeutique deÂl'hypertension artÃ©rielle pulmonaire. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2007, 16, 294-301.	0.1	3
724	Clinical Year in Review IV. Proceedings of the American Thoracic Society, 2012, 9, 204-209.	3.5	3
725	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. European Respiratory Review, 2014, 23, 260-263.	7.1	3
726	Response to Letter Regarding Article, â€œAdvances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertensionâ€• Circulation, 2015, 132, e154.	1.6	3
727	Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. International Journal of Cardiology, 2015, 184, 763-765.	1.7	3
728	To stress or not to stress? Exercise pulmonary haemodynamic testing in systemic sclerosis. European Respiratory Journal, 2016, 48, 1549-1552.	6.7	3
729	Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. Leukemia and Lymphoma, 2017, 58, 2875-2879.	1.3	3
730	Response to the article â€œSorafenib as a potential strategy for refractory pulmonary arterial hypertensionâ€• Pulmonary Pharmacology and Therapeutics, 2017, 45, 11-12.	2.6	3
731	Rare pulmonary diseases: a common fight. European Respiratory Review, 2017, 26, 170059.	7.1	3
732	Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration. European Respiratory Journal, 2020, 55, 2001047.	6.7	3
733	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. European Respiratory Journal, 2021, 57, 2003132.	6.7	3
734	The evolution of the European Respiratory Journal: weathering the publishing pandemic. European Respiratory Journal, 2021, 57, 2100084.	6.7	3
735	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1549-1562.	3.8	3
736	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. American Journal of Transplantation, 2021, 21, 3388-3400.	4.7	3
737	Pulmonary hypertension associated with busulfan. Pulmonary Circulation, 2021, 11, 1-12.	1.7	3
738	Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH). , 2018, , .		3

#	Article	IF	Citations
739	Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET. ERJ Open Research, 2022, 8, 00419-2021.	2.6	3
740	Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2102388.	6.7	3
741	Progression of Pulmonary Venoâ€occlusive Disease Without Pulmonary Hypertension. Pulmonary Circulation, 2022, 12, e12046.	1.7	3
742	The Ten Commandments for 2015 European Society of Cardiologyâ€"European Respiratory Society Guidelines on Pulmonary Hypertension. European Heart Journal, 2016, 37, 5.	2.2	3
743	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease Long-term results of a prospective French multicenter cohort. European Respiratory Journal, 0, , 2102897.	6.7	3
744	Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension. Expert Opinion on Pharmacotherapy, 2006, 7, 1133-1138.	1.8	2
745	Screening for Portopulmonary Hypertension with Transthoracic Echocardiography: Implications for Early Mortality Associated with Liver Transplantation. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 378-379.	5.6	2
746	GuÃa de prÃ¡ctica clÃnica para el diagnÃ³stico y tratamiento de la hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1464.e1-1464.e58.	0.6	2
747	Pulmonary Arterial Hypertension and HIV and Other Viral Infections. Progress in Respiratory Research, 2012, , 105-112.	0.1	2
748	Introduction: Devising a Prognostic Score for Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, S1-S2.	1.6	2
749	Everything you always wanted to know about sarcoidosisâ€¦ but were afraid to ask. Presse Medicale, 2012, 41, e273-e274.	1.9	2
750	A study of magnesium deficiency in human and experimental pulmonary hypertension. Magnesium Research, 2012, 25, 21-27.	0.5	2
751	Could the Cochin risk prediction score be applied in daily practice to predict pulmonary hypertension in systemic sclerosis? Comment on the article by Meune et al. Arthritis and Rheumatism, 2012, 64, 2051-2052.	6.7	2
752	Novelties in the Treatment of Pulmonary Hypertension. Archivos De Bronconeumologia, 2017, 53, 235-236.	0.8	2
753	Increasing confidence in the therapeutic relevance of eosinophils in severe asthma. Lancet Respiratory Medicine,the, 2018, 6, 7-8.	10.7	2
754	Outpatient management of patients with low-risk pulmonary embolism: another piece of evidence. European Heart Journal, 2019, 41, 519-521.	2.2	2
755	Response by Guignabert et al to Letter Regarding Article, â€œSelective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertensionâ€. Circulation Research, 2019, 124, e82-e83.	4.5	2
756	Pandemic treatments on trial: the bigger picture. N of many thinking in an N of one scenario. European Respiratory Journal, 2020, 56, 2002281.	6.7	2

#	Article	IF	Citations
757	Description, Staging and Quantification of Pulmonary Artery Angiophagy in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension. Biomedicines, 2020, 8, 493.	3.2	2
758	Looking forward: key initiatives to improve the care of rare diseases and streamline the delivery of medicines and vaccines in Europe. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L616-L618.	2.9	2
759	Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?. Metabolites, 2021, 11, 784.	2.9	2
760	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers. Pulmonary Circulation, 2022, 12, e12023.	1.7	2
761	HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?. European Heart Journal, 2022, 43, 2209-2211.	2.2	2
762	Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	2.9	2
763	To be or not to beâ€¦ treated with initial combination therapy, that is the (PAH) question. European Respiratory Journal, 2022, 59, 2200390.	6.7	2
764	Screening for pulmonary veno-occlusive disease in heterozygous EIF2AK4 variant carriers. European Respiratory Journal, 2022, 60, 2200760.	6.7	2
765	Bronchial immunoglobulin E production in intrinsic asthma. Revue Francaise D'allergologie Et D'immunologie Clinique, 2003, 43, 229-231.	0.1	1
766	Bosentan for the treatment of scleroderma. Future Rheumatology, 2006, 1, 549-562.	0.2	1
767	The Need for National Registries in Rare Diseases. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 228a-229.	5.6	1
768	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2010, 138, 462-463.	0.8	1
769	The changing face of respiratory physiology: 20 years of progress within the ERS: Clinical Physiology and Integrative Biology Assembly contribution to the celebration of 20 years of the ERS. European Respiratory Journal, 2010, 35, 945-948.	6.7	1
770	Current Challenges in Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 549-550.	2.1	1
771	Translational research in pulmonary hypertension: challenge and opportunity. European Respiratory Journal, 2014, 43, 325-328.	6.7	1
772	Epidemiology and Disease Classification of Pulmonary Hypertension. Respiratory Medicine, 2015, , 21-35.	0.1	1
773	Pulmonary embolism: An update. Presse Medicale, 2015, 44, e373-e376.	1.9	1
774	Pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2016, 22, 399.	2.6	1

#	Article	IF	Citations
775	The ambition of the European Respiratory Journal continues: chapter 5. European Respiratory Journal, 2017, 49, 1602393.	6.7	1
776	Novel Treatments for Airway Disease. New England Journal of Medicine, 2017, 377, 595-598.	27.0	1
777	Lessons from pulmonary hypertension registries. Revista Portuguesa De Cardiologia, 2018, 37, 759-761.	0.5	1
778	Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4â€aminopyridine. Fundamental and Clinical Pharmacology, 2019, 33, 426-427.	1.9	1
779	Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e90-e91.	5.6	1
780	Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?. European Respiratory Journal, 2020, 55, 2000700.	6.7	1
781	Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000962.	6.7	1
782	Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La PiÃ¨ce de RÃ©sistance?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 524-525.	5.6	1
783	Lung and heart-lung transplantation for children with PAH: Dramatic benefits from the implementation of a high-priority allocation program in France. Journal of Heart and Lung Transplantation, 2021, 40, 652-661.	0.6	1
784	A <scp>CELSR1</scp> variant in a patient with pulmonary arterial hypertension. Clinical Genetics, 2021, 100, 771-772.	2.0	1
785	Association between sex and SARS-CoV-2 infection and hospitalisation as a result of COVID-19. Lancet Respiratory Medicine,the, 2021, 9, e75-e76.	10.7	1
786	Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis. Respiratory Medicine, 2020, , 89-108.	0.1	1
787	Pulmonary hypertension associated with sarcoidosis. , 2012, , 166-181.		1
788	Reappraising the effects of pulmonary artery wedge pressure on right ventricular pulsatile loading. , 2018, , .		1
789	Late Breaking Abstract - Screening of pulmonary arterial hypertension in asymptomatic BMPR2 mutation carriers (DELPHI-2 Study). , 2019, , .		1
790	Inflammation in Pulmonary Arterial Hypertension. , 2012, , 213-229.		1
791	Pulmonary Hypertension in Orphan Lung Diseases. , 2015, , 529-539.		1
792	Rare pulmonary disease and orphan drugs: a path to the future. European Respiratory Review, 2019, 28, 190115.	7.1	1

#	Article	IF	Citations
793	Multimodality Imaging of Pulmonary Hypertension: Prognostication of Therapeutic Outcomes. Medical Radiology, 2021, , 225-257.	0.1	1
794	Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. Respiratory Medicine, 2020, , 123-134.	0.1	1
795	Sex and gender in lung health and disease: more than just Xs and Ys. European Respiratory Review, 2021, 30, 210217.	7.1	1
796	Response to: Life-threatening PPHN refractory to NO: therapeutic algorithm. European Journal of Pediatrics, 2022, 181, 425-426.	2.7	1
797	Pulsatile pulmonary artery pressure in a large animal model of chronic thromboembolic pulmonary hypertension: Similarities and differences with human data. Pulmonary Circulation, 2022, 12, e12017.	1.7	1
798	Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. , 0, , 89-104.		1
799	Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 367-368.	2.1	0
800	Chronic thromboembolic pulmonary hypertension (CTEPH): specific disease characteristics and similarities to idiopathic pulmonary arterial hypertension. Clinical Research in Cardiology Supplements, 2010, 5, 12-15.	2.0	0
801	Pulmonary arterial hypertension and the state of limbo. European Respiratory Review, 2010, 19, 264-265.	7.1	0
802	Quarterly Medical Review: Pulmonary involvement in systemic diseases. Presse Medicale, 2011, 40, e23-e24.	1.9	0
803	â€œEffect of different asthma treatments on risk of cold-related exacerbations.â€•H.K. Reddel, C. Jenkins, S. Quirce, M.R. Sears, E.D. Bateman, P.M. O'Byrne, M. Humbert, R. Buhl, T. Harrison, G.G. Brusselle, A. ThorÃ©n, U. SjÃ¶bring, S. Peterson, O. Ã–stlund and G.S. Eriksson.Eur Respir J2011; 38: 584â€“593.: Figure 4. European Respiratory Journal, 2012, 39, 1280-1280.	6.7	0
804	Genetics of Pulmonary Arterial Hypertension and the Concept of Heritable Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 65-75.	0.1	0
805	Drug- and Toxin-Induced Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 76-84.	0.1	0
806	Pulmonary Veno-Occlusive Disease. Progress in Respiratory Research, 2012, , 149-160.	0.1	0
807	Omalizumab in the treatment of severe allergic (IgEâ€mediated) asthma: an update on recent developments. Clinical and Translational Allergy, 2013, 3, O12.	3.2	0
808	Reply: The Reninâ€“Angiotensin System in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1139-1140.	5.6	0
809	Thorax Innovation (TORINO). Presse Medicale, 2013, 42, e301-e302.	1.9	0
810	Does Circulating IL-17 Identify a Subset of Patients With Idiopathic Pulmonary Arterial Hypertension?: Response. Chest, 2015, 148, e132-e133.	0.8	0

#	Article	IF	Citations
811	Management of Scleroderma-Associated Pulmonary Involvement. Current Treatment Options in Rheumatology, 2015, 1, 51-67.	1.4	0
812	Novelties in the Treatment of Pulmonary Hypertension. Archivos De Bronconeumologia, 2017, 53, 235-236.	0.8	0
813	Evolving Concepts in Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 559-560.	2.1	0
814	Prostacyclin for pulmonary hypertension. The Cochrane Library, 2017, , .	2.8	0
815	A unique event for the francophone respiratory community. European Respiratory Journal, 2017, 50, 1701479.	6.7	0
816	Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1364-1365.	5.6	0
817	Lessons from pulmonary hypertension registries. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 759-761.	0.2	0
818	Reply to Voelkel and Newman: The Light at the End of the Long Pulmonary Hypertension Tunnel Brightens. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 820-821.	5.6	0
819	Hypertension pulmonaire et connectivites. Revue Du Rhumatisme Monographies, 2018, 85, 210-220.	0.0	0
820	Rebuttal From Drs Humbert and Lau. Chest, 2019, 156, 1045-1046.	0.8	0
821	Acute Right-Heart Failure in Patients with Chronic Precapillary Pulmonary Hypertension. , 2021, , 301-316.		0
822	Pulmonary hypertension associated with neurofibromatosis type 2. Pulmonary Circulation, 2021, 11, 1-4.	1.7	0
823	Comment on: Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype. European Respiratory Journal, 2021, 58, 2101365.	6.7	0
824	Pulmonary hypertension. Annals of Allergy, Asthma and Immunology, 2021, 127, 512-513.	1.0	0
825	Reply to: Jin et al. and Sun et al.. American Journal of Respiratory and Critical Care Medicine, 2021, , .	5.6	0
826	Polymorphisme du gÃ¨ne codant pour le transporteur de la sÃ©rotonine et hypertension artÃ©rielle pulmonaire. Medecine/Sciences, 2002, 18, 395-397.	0.2	0
827	Late Limited Systemic Sclerosis Patient Who Develops Shortness of Breath on Exertion. , 2011, , 127-137.		0
828	Pulmonary hypertension associated with portal hypertension. , 2011, , 245-250.		0

#	Article	IF	Citations
829	Pulmonary hypertension related to appetite suppressants. , 2011, , 236-244.		0
830	Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis. , 2012, , 182-193.		0
831	Pulmonary hypertension in pulmonary Langerhansâ€™ cell histiocytosis. , 2012, , 161-165.		0
832	Acute Right Heart Failure in Pulmonary Hypertension. , 2014, , 261-275.		0
833	Hematopoietic Stem Cells and Chronic Hypoxia-Induced Pulmonary Vascular Remodelling. Pancreatic Islet Biology, 2015, , 241-256.	0.3	0
834	Clinical Assessment of Pulmonary Hypertension. , 2017, , 403-409.		0
835	Architecture gÃ©nÃ©tique de lâ€™hypertension pulmonaire : des gÃ¨nes aux mÃ©dicaments. Bulletin De L'Academie Nationale De Medecine, 2017, 201, 879-893.	0.0	0
836	Interstitial lung diseases in the 2020s. Presse Medicale, 2020, 49, 104022.	1.9	0
837	Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases. , 2020, , 167-183.		0
838	Right heart failure. , 0, , 32-47.		0
839	ERS statement on chronic thromboembolic pulmonary hypertension. Pulmonologiya, 2022, 32, 13-52.	0.8	0
840	Commemorating World Tuberculosis Day 2022: recent ERJ articles of critical relevance to ending TB and saving lives. European Respiratory Journal, 2022, 59, 2200149.	6.7	0
841	Some take-home messages from the 9th International Meeting on Pulmonary Rare Diseases and Orphan Drugs. European Respiratory Review, 2021, 30, 210258.	7.1	0
842	Title is missing!. , 2020, 15, e0243961.		0
843	Title is missing!. , 2020, 15, e0243961.		0
844	Title is missing!. , 2020, 15, e0243961.		0
845	Title is missing!. , 2020, 15, e0243961.		0
846	The Long March to a Cure for Pulmonary Hypertension. JACC Asia, 2022, 2, 215-217.	1.5	0

#	Article	IF	Citations
847	Erythrocytes are altered in pulmonary arterial hypertension. European Respiratory Journal, 0, , 2200506.	6.7	0
848	Knowledge exchange between patient and pharmacist: a mixed methods study to explore the role of pharmacists in patient education and counselling in asthma and pulmonary arterial hypertension. Annales Pharmaceutiques Francaises, 2022, , .	1.0	0
849	Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report. Respiratory Medicine and Research, 2022, , 100943.	0.6	0